Insufficient scRNA-seq data for expression of PDYN at single-cell level.
Insufficient scRNA-seq data for expression of PDYN at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 67% | 2074.92 | 1783 / 2642 | 63% | 13.37 | 447 / 705 |
ovary | 0% | 0 | 0 / 180 | 39% | 3.66 | 167 / 430 |
adrenal gland | 0% | 0 | 0 / 258 | 12% | 5.71 | 27 / 230 |
stomach | 0% | 0.97 | 1 / 359 | 1% | 0.04 | 3 / 286 |
breast | 0% | 0.20 | 1 / 459 | 0% | 0.04 | 5 / 1118 |
uterus | 0% | 0 | 0 / 170 | 1% | 0.91 | 3 / 459 |
thymus | 0% | 0.17 | 1 / 653 | 0% | 0.25 | 3 / 605 |
skin | 0% | 0.10 | 2 / 1809 | 0% | 0.01 | 2 / 472 |
bladder | 0% | 0 | 0 / 21 | 0% | 0.01 | 2 / 504 |
muscle | 0% | 0.34 | 2 / 803 | 0% | 0 | 0 / 0 |
intestine | 0% | 0 | 0 / 966 | 0% | 0.00 | 1 / 527 |
kidney | 0% | 0 | 0 / 89 | 0% | 0.00 | 1 / 901 |
lung | 0% | 0 | 0 / 578 | 0% | 0.00 | 1 / 1155 |
esophagus | 0% | 0.32 | 1 / 1445 | 0% | 0 | 0 / 183 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
adipose | 0% | 0 | 0 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0 | 0 / 1335 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
liver | 0% | 0 | 0 / 226 | 0% | 0 | 0 / 406 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
pancreas | 0% | 0 | 0 / 328 | 0% | 0 | 0 / 178 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
prostate | 0% | 0 | 0 / 245 | 0% | 0 | 0 / 502 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0007600 | Biological process | sensory perception |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_0098992 | Cellular component | neuronal dense core vesicle |
GO_0043679 | Cellular component | axon terminus |
GO_0005576 | Cellular component | extracellular region |
GO_0043025 | Cellular component | neuronal cell body |
GO_0005886 | Cellular component | plasma membrane |
GO_0098686 | Cellular component | hippocampal mossy fiber to CA3 synapse |
GO_0030425 | Cellular component | dendrite |
GO_0031628 | Molecular function | opioid receptor binding |
GO_0001515 | Molecular function | opioid peptide activity |
Gene name | PDYN |
Protein name | Proenkephalin-B (Beta-neoendorphin-dynorphin) (Preprodynorphin) Proenkephalin-B (Beta-neoendorphin-dynorphin) (Preprodynorphin) [Cleaved into: Alpha-neoendorphin; Beta-neoendorphin; Big dynorphin (Big Dyn); Dynorphin A(1-17) (Dyn-A17) (Dynorphin A); Dynorphin A(1-13); Dynorphin A(1-8); Leu-enkephalin; Rimorphin (Dynorphin B) (Dyn-B) (Dynorphin B(1-13)); Leumorphin (Dynorphin B-29)] Prodynorphin Preprodynorphin |
Synonyms | |
Description | FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress (By similarity). .; FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin (By similarity). .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . FUNCTION: Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opioid activity, it is 700 times more potent than Leu-enkephalin. .; FUNCTION: Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: Leumorphin has a typical opioid activity and may have anti-apoptotic effect. . |
Accessions | Q2YEL0 Q2YEM6 A0A494C197 ENST00000540134.5 ENST00000652436.1 ENST00000651882.1 ENST00000651684.1 A0A494C1E3 A0A494C1U2 A0A494C0B3 ENST00000539905.5 A0A494C0X3 ENST00000651996.1 A0A494C0Y8 P01213 ENST00000650874.1 A0A494C0B1 A0A494C1J4 ENST00000217305.3 ENST00000650937.1 ENST00000651328.1 ENST00000650824.1 |